J. W. Kugler

1.6k total citations
32 papers, 1.1k citations indexed

About

J. W. Kugler is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, J. W. Kugler has authored 32 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 6 papers in Epidemiology. Recurrent topics in J. W. Kugler's work include Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). J. W. Kugler is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Colorectal Cancer Treatments and Studies (6 papers) and HER2/EGFR in Cancer Research (6 papers). J. W. Kugler collaborates with scholars based in United States, Germany and Canada. J. W. Kugler's co-authors include Charles L. Loprinzi, James E. Krook, Roscoe F. Morton, Harry S. Wieand, John A. Laurie, Paul J. Novotny, Marjorie Bateman, Jan Bartel, Robert M. Langdon and Sung‐Hoon Jung and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and JNCI Journal of the National Cancer Institute.

In The Last Decade

J. W. Kugler

32 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. W. Kugler United States	15	616	190	188	163	152	32	1.1k
Daurès Jp France	12	459 0.7×	138 0.7×	188 1.0×	103 0.6×	312 2.1×	50	1.2k
Lissandra Dal Lago Belgium	18	1.2k 1.9×	115 0.6×	305 1.6×	83 0.5×	254 1.7×	54	1.7k
Sophie Broutin France	16	311 0.5×	99 0.5×	213 1.1×	67 0.4×	96 0.6×	48	787
Stavroula Tsiara Greece	15	221 0.4×	295 1.6×	249 1.3×	98 0.6×	87 0.6×	38	1.0k
Jie Ling United States	11	255 0.4×	104 0.5×	195 1.0×	205 1.3×	276 1.8×	18	981
Bindu Kanapuru United States	14	306 0.5×	177 0.9×	82 0.4×	132 0.8×	127 0.8×	40	767
Michal G. Rose United States	18	380 0.6×	254 1.3×	235 1.3×	43 0.3×	294 1.9×	73	1.4k
Phuong K. Morrow United States	24	1.0k 1.7×	198 1.0×	525 2.8×	70 0.4×	396 2.6×	65	1.8k
Fadi Haddad United States	20	562 0.9×	545 2.9×	277 1.5×	85 0.5×	262 1.7×	190	1.7k
David D. Stenehjem United States	18	626 1.0×	219 1.2×	318 1.7×	48 0.3×	402 2.6×	113	1.8k

Countries citing papers authored by J. W. Kugler

Since Specialization

Citations

This map shows the geographic impact of J. W. Kugler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. W. Kugler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. W. Kugler more than expected).

Fields of papers citing papers by J. W. Kugler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. W. Kugler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. W. Kugler. The network helps show where J. W. Kugler may publish in the future.

Co-authorship network of co-authors of J. W. Kugler

This figure shows the co-authorship network connecting the top 25 collaborators of J. W. Kugler. A scholar is included among the top collaborators of J. W. Kugler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. W. Kugler. J. W. Kugler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Grothey, Axel, Daniel A. Nikcevich, Jeff A. Sloan, et al.. (2009). Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial. Journal of Clinical Oncology. 27(15_suppl). 4025–4025. 4 indexed citations

2.

Foster, Nathan R., James E. Krook, J. W. Kugler, et al.. (2009). Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Journal of Clinical Oncology. 27(15_suppl). 8085–8085. 1 indexed citations

3.

Schild, Steven E., David L. Graham, Shauna L. Hillman, et al.. (2009). Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 27(15_suppl). 7544–7544. 2 indexed citations

4.

Halyard, Michele Y., Jeff A. Sloan, James D. Bearden, et al.. (2006). 2367. International Journal of Radiation Oncology*Biology*Physics. 66(3). S414–S414. 1 indexed citations

5.

Jatoi, Aminah, Brittany L. Murphy, Nathan R. Foster, et al.. (2005). Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia: A phase II study from the North Central Cancer Treatment Group. Journal of Clinical Oncology. 23(16_suppl). 4059–4059. 3 indexed citations

6.

Alberts, Steven R., Nathan R. Foster, Roscoe F. Morton, et al.. (2005). PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: a North Central Cancer Treatment Group (NCCTG) randomized phase II study. Annals of Oncology. 16(10). 1654–1661. 83 indexed citations

7.

Steen, Preston D., Kendrith M. Rowland, Tom R. Fitch, et al.. (2005). A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study. Annals of Oncology. 17(2). 226–231. 18 indexed citations

8.

Steen, Preston D., K. M. Rowland, J. W. Kugler, et al.. (2004). A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study. Journal of Clinical Oncology. 22(14_suppl). 639–639. 2 indexed citations

9.

Steen, Preston D., K. M. Rowland, J. W. Kugler, et al.. (2004). A phase II study of a combination of pemetrexed (Pem) and gemcitabine (Gem) in patients with metastatic breast cancer (MBC): An NCCTG study. Journal of Clinical Oncology. 22(14_suppl). 639–639. 7 indexed citations

10.

Bonner, James A., Jeff A. Sloan, Kendrith M. Rowland, et al.. (2000). Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.. PubMed. 6(2). 597–601. 36 indexed citations

11.

Fleming, Gini F., J. W. Kugler, P C Hoffman, et al.. (1998). Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.. Journal of Clinical Oncology. 16(6). 2032–2037. 16 indexed citations

12.

Mani, Sridhar, J. W. Kugler, Rafat Ansari, et al.. (1998). Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced pancreatic carcinoma: A University of Chicago phase II consortium study. Annals of Oncology. 9(9). 1035–1037. 14 indexed citations

13.

Creagan, Edward T., Robert J. Dalton, David L. Ahmann, et al.. (1995). Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma.. Journal of Clinical Oncology. 13(11). 2776–2783. 170 indexed citations

14.

Loprinzi, Charles L., Richard M. Goldberg, John Q. Su, et al.. (1994). Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer.. Journal of Clinical Oncology. 12(6). 1126–1129. 78 indexed citations

15.

Loprinzi, Charles L., John A. Laurie, Harry S. Wieand, et al.. (1994). Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group.. Journal of Clinical Oncology. 12(3). 601–607. 220 indexed citations

16.

Jett, James R., John Q. Su, James E. Krook, Robert M. Goldberg, & J. W. Kugler. (1994). Measurable or assessable disease in lung cancer trials: does it matter?. Journal of Clinical Oncology. 12(12). 2677–2681. 15 indexed citations

17.

Case, Delvyn C., Robert W. Carey, David H. Henry, et al.. (1993). Recombinant Human Erythropoietin Therapy for Anemic Cancer Patients on Combination Chemotherapy. JNCI Journal of the National Cancer Institute. 85(10). 801–806. 154 indexed citations

18.

Edmonson, J H, Harry S. Wieand, J. W. Kugler, et al.. (1989). Cyclophosphamide-Cisplatin Versus Cyclophosphamide-Carboplatin in Stage III-IV Ovarian Carcinoma: A Comparison of Equally Myelosuppressive Regimens. JNCI Journal of the National Cancer Institute. 81(19). 1500–1504. 44 indexed citations

19.

Armitage, Jamés O., Lynell W. Klassen, J. W. Kugler, et al.. (1984). Marrow transplantation for stable-phase chronic granulocytic leukemia.. PubMed. 12(9). 717–9. 10 indexed citations

20.

Blumgart, L.H., et al.. (1964). Experimental Studies with Gastric Freezing. Gastroenterology. 47(3). 291–305. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact